"10.1371_journal.pone.0053292","plos one","2013-01-02T00:00:00Z","Sherene Loi; Stefan Michiels; Jose Baselga; John M S Bartlett; Sandeep K Singhal; Vicky S Sabine; Andrew H Sims; Tarek Sahmoud; J Michael Dixon; Martine J Piccart; Christos Sotiriou","Breast Cancer Translational Research Laboratory (BCTL), Jules Bordet Institute, Brussels, Belgium; Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America; Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Edinburgh Breast Unit, Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; Novartis Pharma, East Hanover, New Jersey, United States of America; Applied Bioinformatics of Cancer Group, Edinburgh Breakthrough Unit, University of Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, United Kingdom; Department of Medicine, Jules Bordet Institute, Brussels, Belgium","Conceived and designed the experiments: SL SM JMSB CS. Performed the experiments: SL SM. Analyzed the data: SL SM. Contributed reagents/materials/analysis tools: JB JMSB SKS VSS AHS TS JMD MJP CS. Wrote the paper: SL SM.","SL and CS are named inventors on a provisional worldwide patent filed by the Universit√© Libre de Bruxelles for the PIK3CA mutation-associated gene signature (PIK3CA-GS). TS is an employee of Novartis Pharma. All the other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Sherene Loi","SL",11,TRUE,4,2,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
